Nutraceutical Interventions for Hypertension: A Comprehensive Review of Current Evidence
Keywords:
N\AAbstract
N\A
Downloads
References
Houston MC. Treatment of hypertension with nutraceuticals, vitamins, antioxidants and minerals. Expert Rev Cardiovasc Ther. 2007;5:681–691. doi: 10.1586/14779072.5.4.681. [DOI] [PubMed] [Google Scholar]
Eaton SB, Eaton SB, Konner MJ. Paleolithic nutrition revisited: a twelve-year retrospective on its nature and implications. Eur J Clin Nutr. 1997;51:207–216. doi: 10.1038/sj.ejcn.1600389. [DOI] [PubMed] [Google Scholar]
Houston MC, Harper KJ. Potassium, magnesium, and calcium: their role in both the cause and treatment of hypertension. J Clin Hypertens (Greenwich) 2008;10:3–11. doi: 10.1111/j.1751-7176.2008.08575.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Layne J, Majkova Z, Smart EJ, Toborek M, Hennig B. Caveolae: a regulatory platform for nutritional modulation of inflammatory diseases. J Nutr Biochem. 2011;22:807–811. doi: 10.1016/j.jnutbio.2010.09.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
Dandona P, Ghanim H, Chaudhuri A, Dhindsa S, Kim SS. Macronutrient intake induces oxidative and inflammatory stress: potential relevance to atherosclerosis and insulin resistance. Exp Mol Med. 2010;42:245–253. doi: 10.3858/emm.2010.42.4.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
Berdanier CD. Nutrient-gene interactions. In: Ziegler EE, Filer LJ Jr, eds , editors. Present Knowledge in Nutrition, 7th Ed. Washington. DC: ILSI Press; 1996. pp. 574–580. [Google Scholar]
Talmud PJ, Waterworth DM. In-vivo and in-vitro nutrient-gene interactions. Curr Opin Lipidol. 2000;11:31–36. doi: 10.1097/00041433-200002000-00005. [DOI] [PubMed] [Google Scholar]
Lundberg AM, Yan ZQ. Innate immune recognition receptors and damage-associated molecular patterns in plaque inflammation. Curr Opin Lipidol. 2011;22:343–349. doi: 10.1097/MOL.0b013e32834ada80. [DOI] [PubMed] [Google Scholar]
Zhao L, Lee JY, Hwang DH. Inhibition of pattern recognition receptor-mediated inflammation by bioactive phytochemicals. Nutr Rev. 2011;69:310–320. doi: 10.1111/j.1753-4887.2011.00394.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Houston MC. The importance of potassium in managing hypertension. Curr Hypertens Rep. 2011;13:309–317. doi: 10.1007/s11906-011-0197-8. [DOI] [PubMed] [Google Scholar]
Broadhurst CL. Balanced intakes of natural triglycerides for optimum nutrition: an evolutionary and phytochemical perspective. Med Hypotheses. 1997;49:247–261. doi: 10.1016/s0306-9877(97)90210-3. [DOI] [PubMed] [Google Scholar]
Eftekhari A, Mathiassen ON, Buus NH, Gotzsche O, Mulvany MJ, Christensen KL. Disproportionally impaired microvascular structure in essential hypertension. J Hypertens. 2011;29:896–905. doi: 10.1097/HJH.0b013e3283447a1c. [DOI] [PubMed] [Google Scholar]
Touyz RM. New insights into mechanisms of hypertension. Curr Opin Nephrol Hypertens. 2012;21:119–121. doi: 10.1097/MNH.0b013e328350a50f. [DOI] [PubMed] [Google Scholar]
Xing T, Wang F, Li J, Wang N. Hypertension: an immunologic disease. J Hypertens. 2012;30:2440–2441. doi: 10.1097/HJH.0b013e32835953f9. [DOI] [PubMed] [Google Scholar]
Giannattasio C, Cattaneo BM, Mangoni AA, Carugo S, Stella ML, Failla M, Trazzi S, Sega R, Grassi G, Mancia G. Cardiac and vascular structural changes in normotensive subjects with parental hypertension. J Hypertens. 1995;13:259–264. [PubMed] [Google Scholar]
Goncharov A, Bloom M, Pavuk M, Birman I, Carpenter DO. Blood pressure and hypertension in relation to levels of serum polychlorinated biphenyls in residents of Anniston, Alabama. J Hypertens. 2010;28:2053–2060. doi: 10.1097/HJH.0b013e32833c5f3e. [DOI] [PubMed] [Google Scholar]
17.Houston MC. Role of mercury toxicity in hypertension, cardiovascular disease, and stroke. J Clin Hypertens (Greenwich) 2011;13:621–627. doi: 10.1111/j.1751-7176.2011.00489.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Al-Ghamdi A. Role of herpes simplex virus-1, cytomegalovirus and Epstein-Barr virus in atherosclerosis. Pak J Pharm Sci. 2012;25:89–97. [PubMed] [Google Scholar]
19.Kotronias D, Kapranos N. Herpes simplex virus as a determinant risk factor for coronary artery atherosclerosis and myocardial infarction. In Vivo. 2005;19:351–357. [PubMed] [Google Scholar]
Grahame-Clarke C, Chan NN, Andrew D, Ridgway GL, Betteridge DJ, Emery V, Colhoun HM, Vallance P. Human cytomegalovirus seropositivity is associated with impaired vascular function. Circulation. 2003;108:678–683. doi: 10.1161/01.CIR.0000084505.54603.C7. [DOI] [PubMed] [Google Scholar]
Nayak DU, Karmen C, Frishman WH, Vakili BA. Antioxidant vitamins and enzymatic and synthetic oxygen-derived free radical scavengers in the prevention and treatment of cardiovascular disease. Heart Dis. 2001;3:28–45. doi: 10.1097/00132580-200101000-00006. [DOI] [PubMed] [Google Scholar]
Kizhakekuttu TJ, Widlansky ME. Natural antioxidants and hypertension: promise and challenges. Cardiovasc Ther. 2010;28:e20–e32. doi: 10.1111/j.1755-5922.2010.00137.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Kitiyakara C, Wilcox CS. Antioxidants for hypertension. Curr Opin Nephrol Hypertens. 1998;7:531–538. doi: 10.1097/00041552-199809000-00008. [DOI] [PubMed] [Google Scholar]
Russo C, Olivieri O, Girelli D, Faccini G, Zenari ML, Lombardi S, Corrocher R. Anti-oxidant status and lipid peroxidation in patients with essential hypertension. J Hypertens. 1998;16:1267–1271. doi: 10.1097/00004872-199816090-00007. [DOI] [PubMed] [Google Scholar]
Tse WY, Maxwell SR, Thomason H, Blann A, Thorpe GH, Waite M, Holder R. Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial damage. J Hum Hypertens. 1994;8:843–849. [PubMed] [Google Scholar]
Mansego ML, Solar Gde M, Alonso MP, Martínez F, Sáez GT, Escudero JC, Redón J, Chaves FJ. Polymorphisms of antioxidant enzymes, blood pressure and risk of hypertension. J Hypertens. 2011;29:492–500. doi: 10.1097/HJH.0b013e328341f1b2. [DOI] [PubMed] [Google Scholar]
Galley HF, Thornton J, Howdle PD, Walker BE, Webster NR. Combination oral antioxidant supplementation reduces blood pressure. Clin Sci (Lond) 1997;92:361–365. doi: 10.1042/cs0920361. [DOI] [PubMed] [Google Scholar]
Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18:655–673. doi: 10.1097/00004872-200018060-00002. [DOI] [PubMed] [Google Scholar]
29.Saez G, Tormos MC, Giner V, Lorano JV, Chaves FJ, Armengod ME, Redon J. P-653: Oxidative stress and enzymatic antioxidant mechanisms in essential hypertension. Am J Hypertens. 2001;14:248A. [Google Scholar]
Nishihara M, Hirooka Y, Matsukawa R, Kishi T, Sunagawa K. Oxidative stress in the rostral ventrolateral medulla modulates excitatory and inhibitory inputs in spontaneously hypertensive rats. J Hypertens. 2012;30:97–106. doi: 10.1097/HJH.0b013e32834e1df4. [DOI] [PubMed] [Google Scholar]
Konno S, Hirooka Y, Kishi T, Sunagawa K. Sympathoinhibitory effects of telmisartan through the reduction of oxidative stress in the rostral ventrolateral medulla of obesity-induced hypertensive rats. J Hypertens. 2012;30:1992–1999. doi: 10.1097/HJH.0b013e328357fa98. [DOI] [PubMed] [Google Scholar]
Ghanem FA, Movahed A. Inflammation in high blood pressure: a clinician perspective. J Am Soc Hypertens. 2007;1:113–119. doi: 10.1016/j.jash.2007.01.004. [DOI] [PubMed] [Google Scholar]
Amer MS, Elawam AE, Khater MS, Omar OH, Mabrouk RA, Taha HM. Association of high-sensitivity C-reactive protein with carotid artery intima-media thickness in hypertensive older adults. J Am Soc Hypertens. 2011;5:395–400. doi: 10.1016/j.jash.2011.03.004. [DOI] [PubMed] [Google Scholar]
Vongpatanasin W, Thomas GD, Schwartz R, Cassis LA, Osborne-Lawrence S, Hahner L, Gibson LL, Black S, Samols D, Shaul PW. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation. 2007;115:1020–1028. doi: 10.1161/CIRCULATIONAHA.106.664854. [DOI] [PubMed] [Google Scholar]
Razzouk L, Muntner P, Bansilal S, Kini AS, Aneja A, Mozes J, Ivan O, Jakkula M, Sharma S, Farkouh ME. C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. Am Heart J. 2009;158:277–283. doi: 10.1016/j.ahj.2009.05.026. [DOI] [PubMed] [Google Scholar]
Kvakan H, Luft FC, Muller DN. Role of the immune system in hypertensive target organ damage. Trends Cardiovasc Med. 2009;19:242–246. doi: 10.1016/j.tcm.2010.02.004. [DOI] [PubMed] [Google Scholar]
Rodríguez-Iturbe B, Franco M, Tapia E, Quiroz Y, Johnson RJ. Renal inflammation, autoimmunity and salt-sensitive hypertension. Clin Exp Pharmacol Physiol. 2012;39:96–103. doi: 10.1111/j.1440-1681.2011.05482.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Tian N, Penman AD, Mawson AR, Manning RD, Flessner MF. Association between circulating specific leukocyte types and blood pressure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Hypertens. 2010;4:272–283. doi: 10.1016/j.jash.2010.09.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
Muller DN, Kvakan H, Luft FC. Immune-related effects in hypertension and target-organ damage. Curr Opin Nephrol Hypertens. 2011;20:113–117. doi: 10.1097/MNH.0b013e3283436f88. [DOI] [PubMed] [Google Scholar]
Marketou ME, Kontaraki JE, Zacharis EA, Kochiadakis GE, Giaouzaki A, Chlouverakis G, Vardas PE. TLR2 and TLR4 gene expression in peripheral monocytes in nondiabetic hypertensive patients: the effect of intensive blood pressure-lowering. J Clin Hypertens (Greenwich) 2012;14:330–335. doi: 10.1111/j.1751-7176.2012.00620.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Luft FC. Neural regulation of the immune system modulates hypertension-induced target-organ damage. J Am Soc Hypertens. 2012;6:23–26. doi: 10.1016/j.jash.2011.09.006. [DOI] [PubMed] [Google Scholar]
Herrada AA, Campino C, Amador CA, Michea LF, Fardella CE, Kalergis AM. Aldosterone as a modulator of immunity: implications in the organ damage. J Hypertens. 2011;29:1684–1692. doi: 10.1097/HJH.0b013e32834a4c75. [DOI] [PubMed] [Google Scholar]
Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens. 2013;31:3–15. doi: 10.1097/HJH.0b013e3283599b6a. [DOI] [PubMed] [Google Scholar]
Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117–1124. doi: 10.1056/NEJM199704173361601. [DOI] [PubMed] [Google Scholar]
Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER, Simons-Morton DG, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3–10. doi: 10.1056/NEJM200101043440101. [DOI] [PubMed] [Google Scholar]
Sun B, Williams JS, Svetkey LP, Kolatkar NS, Conlin PR. Beta2-adrenergic receptor genotype affects the renin-angiotensin-aldosterone system response to the Dietary Approaches to Stop Hypertension (DASH) dietary pattern. Am J Clin Nutr. 2010;92:444–449. doi: 10.3945/ajcn.2009.28924. [DOI] [PMC free article] [PubMed] [Google Scholar]
Chen Q, Turban S, Miller ER, Appel LJ. The effects of dietary patterns on plasma renin activity: results from the Dietary Approaches to Stop Hypertension trial. J Hum Hypertens. 2012;26:664–669. doi: 10.1038/jhh.2011.87. [DOI] [PubMed] [Google Scholar]
Al-Solaiman Y, Jesri A, Zhao Y, Morrow JD, Egan BM. Low-Sodium DASH reduces oxidative stress and improves vascular function in salt-sensitive humans. J Hum Hypertens. 2009;23:826–835. doi: 10.1038/jhh.2009.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
Lin PH, Allen JD, Li YJ, Yu M, Lien LF, Svetkey LP. Blood Pressure-Lowering Mechanisms of the DASH Dietary Pattern. J Nutr Metab. 2012;2012:472396. doi: 10.1155/2012/472396. [DOI] [PMC free article] [PubMed] [Google Scholar]
Kotchen TA, McCarron DA. Dietary electrolytes and blood pressure: a statement for healthcare professionals from the American Heart Association Nutrition Committee. Circulation. 1998;98:613–617. doi: 10.1161/01.cir.98.6.613. [DOI] [PubMed] [Google Scholar]
Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr. 1997;65:643S–651S. doi: 10.1093/ajcn/65.2.643S. [DOI] [PubMed] [Google Scholar]
Svetkey LP, Sacks FM, Obarzanek E, Vollmer WM, Appel LJ, Lin PH, Karanja NM, Harsha DW, Bray GA, Aickin M, et al. The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-sodium): rationale and design. DASH-Sodium Collaborative Research Group. J Am Diet Assoc. 1999;99:S96–104. doi: 10.1016/s0002-8223(99)00423-x. [DOI] [PubMed] [Google Scholar]
Kawada T, Suzuki S. Attention of salt awareness to prevent hypertension in the young. J Clin Hypertens (Greenwich) 2011;13:933–934. doi: 10.1111/j.1751-7176.2011.00555.x
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
